Fundies.
English

Segment disclosures

Company overview

PROGENICS PHARMACEUTICALS INC

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

5 dimension combinations 8 retained observations 6 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Cytodyn Agreement

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=pgnx:CytodynAgreementMember
PeriodValueUnitFiledEvidence
2015-10-01 – 2015-12-311500000 U00120160311Open filing evidence

Cytodyn

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=pgnx:CytodynMember
PeriodValueUnitFiledEvidence
2013-10-01 – 2013-12-312800000 U00120140313Open filing evidence
2012-10-01 – 2012-12-312800000 U00120130315Open filing evidence

Fuji

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=pgnx:FujiMember
PeriodValueUnitFiledEvidence
2014-01-01 – 2014-03-311000000 U00120160311Open filing evidence

Medimmune

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=pgnx:MedimmuneMember
PeriodValueUnitFiledEvidence
2013-10-01 – 2013-12-315000000 U00120140313Open filing evidence
2012-10-01 – 2012-12-315000000 U00120130315Open filing evidence

Salix

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=pgnx:SalixMember
PeriodValueUnitFiledEvidence
2014-07-01 – 2014-09-3040000000 U00120160311Open filing evidence
2011-04-01 – 2011-06-3059500000 U00120130315Open filing evidence